EX-99.1 2 ptn_ex991.htm PRESS RELEASE EXHIBIT 99.1 Palatin Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update · Positive Phase 3 PL9643 MELODY-1 Pivotal Study Results o Co-Primary Symptom Endpoint of Pain Met Statistical Significance (P<0.025) and 7 of 11 Secondary Symptom Endpoints Met Statistical Significance (P<0.05), at the12-Week Treatment Period o Rapid Onset of Efficacy and Multiple Symptom Endpoints, Including the Co-Primary Pain Endpoint, Met Statistical Signific ...